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Toxic shock syndrome toxin-1 (TSST-1) is a bacterial superantigen that causes toxic shock 
in humans, probably by poly clonal activation of T -cells resulting from the cross linking of 
class D major histocompatability complex (MHC) molecules of antigen-presenting cells to 
the antigen receptors of T-cells (TCRs). The X-ray crystal structures of the complexes 
between superantigens and the human class D MHC molecule HLA-DRl have revealed 
the molecular basis of the interaction between two proteins. However, structural studies of 
the TCR:superantigen complex have been hampered primarily by the lack of sufficient 
amounts of homogeneous TCR protein. Here we report the preparation of large amounts 
of a soluble ~-chain TCR and its interaction with TSST-1. The ~-chain TCR was ex-
pressed in E. coli as inclusion bodies. The inclusion body protein was refolded with an ef-
ficiency of 10-15% by a dialysis method in the presence of a reduced/oxidized glutathione 
redox buffer. The refolded ~-chain TCR binds specifically to TSST-1 with a binding in-
teraction strong enough to be detected by native gel shift assay and to make it possible to 
purify the complex by gel-filtration chromatography. 
Toxic shock syndrome toxin-1 (TSST -1) is a bac-
terial superantigen that causes toxic shock in humans, 
probably by polyclonal activation of T-cells (Marrack 
et ai., 1990) that results in overproduction of lym-
phokines (Miethke et al., 1992). Selective expansion 
of T-cells expressing the V~2 family of T-cell an-
tigen receptor (TCR) ~-chains was observed in pa-
tients with toxic shock syndrome (Choi et ai., 1990). 
The activation of larg'1 numbers of mature T-cells by 
TSST -1 and other ~uperantigens results from the 
cross linking of class II major histocompatability com-
plex (MHC) molecules of antigen presenting cells to 
the antigen receptors of T -cells (Fleischer and 
Schrezenmeier, 1988; Marrack and Kappler, 1990). 
Earlier studies indicate that superantigens function as 
intact molecules (Fleischer and Schrezenmeier, 1988), 
and bind primarily outside of the peptide binding 
groove of class II MHC molecules and to the fourth 
hypervariable loop (HV4) of TCRs (Fleischer and 
Mittlllcker, 1991; Pullen et al., 1991; Seth et ai., 
1994). 
The X-ray crystal structures of the human class II 
* To whom correspondence should be addressed. 
MHC molecule HLA-DR1 complexed with the su-
perantigen staphylococcal enterotoxin B (SEB; Jar-
detzky et ai., 1994) and TSST-1 (Kim et ai., 1994) re-
vealed the molecular basis of the interaction between 
superantigen and class II MHC molecules. SEB binds 
exclusively to the a-chain of DR1 off one edge of 
the peptide binding groove. Interestingly, one loop of 
SEB contacts polymorphic residues of DR1 re-
cognized by the TCR during conventional antigen re-
cognition, suggesting an uncoventional model for the 
interaction between the TCR and MHC during su-
perantigen activation. The TSST -1 binding site on 
DR1 overlaps that of SEB, but the two binding 
modes are very different, although the tertiary struc-
tures of SEB and TSST-1 are similar (Acharya et ai., 
1994; Prasad et ai., 1993; Swaminathan et ai., 1992). 
While SEB binds primarily off one edge of the DR1 
peptide binding site, TSST-1 extends over almost one-
half of the binding site contacting both the flanking 
MHC a-helices and the bound peptide. This suggests 
The abbreviations used are: MHC, major histo-
compatability complex; TSST-l, toxic shock syndrome tox- ' 
in-I; TCRs, receptors of T-cells. 
© 1996 The Korean Society for Molecular Biology 
Vol. 6 (1996) Jongsun Kim et al. 591 
that TCR would bind to TSST-1:DR1 complex very 
differently than to DRl:peptide complex or SEB:DRI 
complex. 
However, structural studies of the TCR and TCR: 
superantigen complex have been hampered primarily 
by the lack of sufficient amounts of homogeneous 
TCR protein. As a result, our understanding of the 
molecular basis of the interaction between su-
perantigen and TCR is very limited, compared to that 
of superantigen: MHC complex. Here we report the 
preparation of large amounts of a soluble ~-chain 
TCR and its interaction with TSST-l. The ~-chain 
TCR was expressed in E. coli as inclusion bodies. 
The inclusion body protein was refolded in vitro. The 
refolded ~-chain TCR binds specifically to TSST-1 
and the binding interaction is strong enough to be de-
tected by native gel shift assay and to allow pu-
rification of the complex by gel-filtration chro-
matography. 
Materials and Methods 
Gene sources and bacterial strains 
The human TCR ~-chain (V~2.10, J~2.1 and C~2) 
was obtained by PCR cloning from peripheral blood 
lymphocytes that had been repetitively stimulated 
with TSST-1 (Utz et al. , unpublished results). The 
TCR ~-chain was expressed in E. coli with the ex-
pression vector pLMl containing a T7 promoter 
(Sodeoka et aI., 1993). The E. coli strain DH5a was 
used for DNA manipulation and the BL21 (DE3) 
plysS was used for protein expression (Studier et aI., 
1990). The recombinant DNA of the TCR ~-chain 
(pB2.10) contains the protein coding region of the ex-
tracellular domain (amino acids 1-254, Fig. 1a). 
Materials 
TSST-1 and SEB were purchased from Toxin Tech-
nology (Tampa, FL). 
Truncation of the ~-chain TCR 
The C-terplinal region of the ~-chain TCR (amino 
acids 233-254) was truncated by using PCR with pB2. 
10 as the template and the oligonucleotide primers 5'-
GATACTGCCTGAGCAGCCGCCTGAGG-3' and 5'-
GTTTCAAAGCTTTACTGGGTGACGGGTTTGGC-
3', containing the underlined Bsu36I and HindIII res-
triction sites, respectively. The stop codon TAA at co-
don 233 was included in the HindIII recognition site. 
The amplification mixture (100 ,.11) contained dGTP, 
dATP, dTTP, dCTP (each 200 )..tM), oligonucleotide 
primers (each 1 )..tM), template DNA (20 ng) and Taq 
polymerase (Boeringer Manheim) in 50 roM Tris-HCI 
(PH 9.0)150 mM NaCl/10 roM MgCI2. The reaction 
mixture was subjected to 25 cycles of 94 ·0 for 1 
min, 55 ·0 for 1 min, 72 ·0 for 1 min, and a final 2 
min at 72 ·0. The amplified DNAs were gel-purified, 
digested with Bsu36I/HindIII, and ligated into pB2.10 
that had been digested with Bsu36I/HindIII and gel-
purified. The plasmid was transformed into E. coli 
DH5a, and clones containing the correct insert were 
identified by agarose gel electrophoresis. One clone 
was subjected to DNA sequencing to verify its se-
quence and the plasmid (pB2.1O-S) was transformed 
into E. coli BL21 (DE3) plysS for expression of the 
truncated form of ~2.10 TCR (amino acid 1-232). 
Another recombinant plasmid of the ~-chain TCR 
(pB2.1O-M) that expresses a truncated form of ~­
chain TCR (amino acid 1-243) was constructed with 
the same method. The oligonucleotide primers used 
were 5'-GATACTGCCTGAGCAGCCGCCTGAGG-3' 
and 5'-GTTTCAAAGCTITAGTCTGCTCTACCCC-
AGGCCTC-3', containing the under-lined Bsu36I and 
HindIII restriction sites, respectively. 
Preparation of inclusion bodies 
Six liters of bacteria transformed with pB2.1O-S 
and pB2.1O-M, respectively, were incubated at 37 ·0 
and induced with 0.5 mM isopropyl-~-D-thiogalac­
to side at OD650 of 0.6-0.8. Four hours after the in-
duction, bacteria were harvested by centrifugation, 
and inclusion bodies (insoluble protein aggregates) 
were isolated as described by Nagai and Thogersen 
(1987), with the modification of a freeze and thaw 
step after detergent treatment of the bacteria 
(Garboczi et al., 1996). After washing four times 
with the Triton solution and one time with the Tris 
solution, the inclusion body pellet was dissolved in 20 
rnl of 8 M Urea in 50 mM MES (PH 6.5) with 1 roM 
EDTA and 1 mM DTT. Insoluble material was pel-
leted by centrifugation at 15,000 rpm for 30 min at 
room temperature, and the protein solution was stored 
at - 70 ·0 in aliquots. 
Refolding of the ~-chain TCR 
Inclusion body protein of the TCR ~-chain was re-
folded by a dialysis method in the presence of a 
reduced/oxidized glutathione redox buffer (Garboczi 
et ai., 1996). About 20 mg of inclusion body solution 
was diluted with 30 ml of 8 M urea in 20 roM Tris 
(PH 8.0), and further diluted with 400 rnl of 0.1 M 
Trois-Hel (PH 8.0)10.4 M L-Arginine/4.5 M Urea/2 
mM EDTN5 )..tg/rnl leupeptin/5 roM reduced glu-
tathione/0.5 mM oxidized glutathione. The solution 
was dialyzed against 4 liters of 0.1 M Tris-HCI (PH 
8.0)/0.4 M L-Arginine/2 M Urea/2 mM EDTA for 2 
days at 4 ·0, and was further dialyzed against 4 liters 
of 20 mM Tris-HCI (PH 8.0)10.15 M NaCl/l mM 
EDTNO.5 mM DTT for 1 day at 4 ·0, and finally 
against 4 liters of 20 roM Tris-HCI (PH 8.0)/1 mM 
EDTNO.5 roM DTT for 1 day at 4 ·0. 
Purification of refolded protein 
The refolding mixture was applied to a DEAE 
Sepharose column equilibrated in 20 roM Tris-HCI 
(PH 8.0) and eluted with 20 mM Tris-HCI (PH 8.0)/ 
0.4 M NaC!. The fractions were analyzed by SDS-
PAGE under non-reducing conditions, and the frac-
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tions containing the correctly folded protein were 
pooled and concentrated with a Centriprep-30 and a 
Centricon-30 (Amicon) to 0.5 mi. The concentrated 
protein was subjected to a FPLC gel filtration column 
equilibrated in 20 mM Tris buffer (PH 7.5), and the 
peak with the appropriate mobility was collected. The 
peak fractions were concentrated with a Centricon-30 
to 250 Jll. 
peripheral bl09d lymphocytes from a normal blood 
donor were stimulated repeatedly with TSST -1 and 
the activated lymphocytes were shown to be TSST-1 
specific in proliferation assays prior to PCR analysis. 
The amino acid sequence of the cloned TCR p-chain 
shown in Figure 1a indicates that the TCR p-chain 
uses the genes Vp2.10, Jp2.1, and CP2 (Rowen et ai., 
1996). This is consistent with the observation that pa-
tients with toxic shock syndrome exhibit selective ex-
pansion of T cells expressing the VP2 family of TCR 
p-chains (Choi et al. , 1990). 
Results 
eDNA cloning of a TCR p-ehain 
A TCR p-chain cDNA was cloned from peripheral 
blood lymphocytes by PCR with V-region-specific 
and C-region-specific primers (Utz et al., 1996). The 
TCR and the Fab domain of immunoglobulin 
u- and p-chains of TCR belong to the im-
munoglobulin (Ig) super-family. Particularly, the am-
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Figure 1. (a) Amino acid sequence alignment of the constant domains of the Ig light chain, TCR a-chain, and TCR ~-chain . 
Amino acid sequences were aligned with the BESTFIT program of the GCG package, and edited manually based on the 
secondary structural information of the Ig light chain. Cysteine residues which form an intra-molecular disulfide bond are 
bold and the cysteine residue which forms an inter-chain disulfide bridge to the a-chain is marked with an asterisk. TCR ~­
chain is aligned two ways, I and II, depending on the location of the inserted sequence element found in TCR ~-chains. The 
amino acid sequence of the variable domain of the doned TCR ~-chain (V~2. 1O) is MGA VVSQHPS RVICKSGTSV 
KIECRSLDFQ ATIMFWYRQF PKQSLMLMAT SNEGSKATYE QGVEKDKFLI NHASLTLSTL TVTSAHPEDS 
SFYICSAAFN EQFFGPGTRL TVLEDLKNVF P 121. (b) Map for the three ~2. 1O TCR constructs. Translational stop co-
dons were substituted for the amino acid residue 255 in p2.10-L, for the C-telllinal-most cysteine codons (Cys244) in P2.l0-
M, and for the amino acid residue 233 in ~2.1O-S . Cysteine residues are labeled -S, disulfide bonds are -S-S-, and the cys-
teine residue that forms an inter-chain disulfide bridge to the a-chain is marked with an asterisk. ; 
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Figure 2. (a) FPLC gel-filtration profile of the ~2.10-L TCR. A Superdex 75 column (Pharmacia) equilibrated in 20 mM 
Tris buffer (PH 7.5) was used for final purification. SDS PAGE analysis indicates that peak 1 consists of aggregated ~-chain 
TCR, and peak 2 consists of correctly folded ~-chain . (b) FPLC gel-filtration profile of the ~2.1O-M TCR. Superdex 200 
column (Pharmacia) equilibrated in 20 mM Tris buffer (PH 7.5) was used for final purification. SDS PAGE analysis in-
dicates that peak 1 consists of aggregated ~-chain TCR, and peak 2 consists of correctly folded ~-chain. (c) FPLC gel-fil-
tration profile of the ~2. 10-S TCR. Superdex 75 column (pharmacia) equilibrated in 20 mM Tris buffer (PH 7.5) was used 
for final purification. SDS PAGE analysis indicates that peak 1 consists of aggregated ~-chain TCR. 
ino acid sequence of TCR is homologous to the Fab 
domain of antibody. The structural model of TCR 
has been proposed based on the tertiary structure of 
the Fab domain (Chothia et ai., 1988; Davis and 
Bjorkman, 1988; Claverie et al., 1989; Novtny et al., 
1986) and the structure of some TCR domains 
(Bentley et al., 1995; Fields et al., 1995). In order to 
determine the exact position of the extracellular 
domain of TCR, we aligned the amino acid se-
quences of TCR a- and ~-chains with that of Ig light 
chain whose three-dimensional structure is known. 
We found that TCR ~-chain has a unique inserted se-
quence element between the second cysteine residue 
of the constant domain and the last cysteine residue, 
which forms a disulfide bridge with the a -chain (Fig. 
1a). We made three constructs of ~2.10 TCR (Fig. 1b) 
to address where the inserted sequence element is lo-
cated on the three dimensional structure and whether 
the inserted sequence element is important for main-
taining the three dimensional structure of ~-chain 
TCR (see below). 
Expression of the ~-chain TCR 
The human TCR ~-chain (V~2.10) was expressed 
in E. coli. To create polypeptides of the extracellular 
domain of the TCR ~-chain, translation stop codons 
were substituted for the C-terminal-most cysteine co-
dons (Cys 244) in our second construct (Fig. 1b, ~2. 
10-M, mid-size form) and stop co dons were placed at 
amino acid residue 233 in our third construct (Figure 
1b, ~2.10-S, short form). This may correspond to the 
C-terminal-most cysteine residue of immunoglobulin 
light chain if the inserted sequence element found in 
TCR ~-chain is not structurally important (Figure 1a). 
The ~-chains produced by the second and third con-
structs each lack the cysteine residue that is located 
close to the transmembrane domain and is involved 
in the inter-molecular disulfide bond with the a-chain 
(Allison et ai., 1982). Both polypeptides were ex-
pressed in large quantities as inclusion bodies in E. 
coli. Lysing the bacterial cells by freeze and thaw 
method with lysozyme and detergents and washing 
the inclusion bodies several times with Triton solu-
tion yielded highly purified proteins of up to 30-50 
mg per liter of bacteri'al culture. The purified in-
clusion body protein was over 80% pure as deter-
mined on SDS gels. 
Refolding of the ~-chain TCR 
The ~-chain TCRs solubilized in urea solution 
were refolded by removal of the denaturant by di-
alysis under dilute condition in the ' presence of a 
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Figure 3. Native gel-shift assay reveals that the refolded 
~-chain TCR (~2 . 1O-M) forms a specific complex with 
TSST-1. 
reduced/oxidized glutathione redox buffer. The extent 
of refolding was analyzed by FPLC gel-filtration chro-
matography and SDS PAGE. Figure 2 shows the typ-
ical FPLC gel-filtration profiles of three refolded ~­
chain TCR proteins (~2 . 10-L, M and S). In figure 2a, 
peak 1 at 7 ml, the void volume of the column con-
sists of aggregated ~-chain, and peak 2 at 9 ml con-
sists of correctly folded ~-chain (~2 . 1O-L) . FPLC gel-
filtration profile of ~2 . 10-M also exibits two major 
peaks, 1 for aggregates and 2 for correctly folded ~­
chain (Figure 2b). ~2.1O-L and ~2.10-M were re-
folded with an final efficiency of 10-15% but ~2.1O­
S was not refolded at all (figure 2c). In Figure 2c, 
peak 1 at the void volume of the column consists of 
aggregated ~2.10-S TCR. Refolding of ~2 . 1O-S by 
the dilution method (Garboczi et al., 1992) gave the 
same result. The refolding method described here 
may be of general utility in refolding other TCR ~­
chains. In fact, two other TCR ~-chains (~6.4 and ~ 
12.1) were efficiently refolded using this method (Fig. 
3; Garboczi et al., 1996). 
Binding of TSST-J to the ~-chain TCR 
The interaction of a soluble ~-chain TCR (~2 . 10-M) 
with TSST-1 was observed using non-denaturing 
PAGE (Fig. 3). The complex of the ~-chain TCR and 
TSST-1 appeared as a prominent shifted band that mi-
grated at a position, distinct from either ~-chain TCR 
or TSST-1 alone. A similar band shift was observed 
with the longer version of ~2.1O TCR (~2 . 10-L) and 
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Figure 4. Purification of TSST-I:~2.10 TCR complex by 
FPLC gel-filtration chromatography. Superdex 75 column e-
quilibrated in 20 mM Tris buffer (PH 7.5) was used and 
the peak fractions were analyzed by SDS PAGE. The first 
peak from gel-filtration chromatography contains both the 
~-chain TCR and TSST-1 (lane 1), and the second peak 
contains the ~-chain TCR or TSST-1 depending on which 
component is added in excess. Lane M, size marker pro-
teins (97, 66, 45, 31, 21.5 and 14.5 kDa from the top). 
band was confirmed by immunoblot analysis using an 
anti-TCR antibody (data not shown). However, the 
binding interactions of the ~2 . 10 TCR with SEB and 
that of the ~6.4 TCR with TSST-1 (Fig. 3) were not 
detected by the gel shift assay, indicating that the in-
teraction between the ~2 . 1O TCR and TSST-1 is high-
ly specific. 
Purification of TSST-J :~-chain TCR complex 
The complex formation of soluble ~-chain TCR 
with TSST-l was also observed using FPLC gel-fil-
tration chromatography. The FPLC gel-filtration chro-
matography profile of a mixture of the ~-chain TCR 
and TSST-1 usually exhibited two well separated 
peaks (Fig. 4). SDS-PAGE analysis of the peaks re-
vealed that the first peak contained both the TCR ~­
chain and TSST-l proteins (Fig. 4), and the second 
peak contained the ~-chain TCR or TSST-l de-
pending on which component was added in excess. 
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Interestingly, the Coomassie blue staining intensity of 
~-chain TCR and TSST-1 bands looked similar, sug-
gesting that the molar ratio of the ~-chain TCR and 
TSST-1 may be 1:1. 
Discussion 
Amino acid sequence comparison of TCR and im-
munoglobulin (Ig) has indicated that TCR is homo-
logous to the Fab domain of Ig. Based on the se-
quence homology with the Fab domain, a structural 
model of TCR has been proposed (Chothia et ai., 
1988; Davis and Bjorkman, 1988). We also com-
pared the amino acid sequence of TCR with that of 
Ig light chain to determine exactly which portion of 
TCR may correspond to the Fab domain of Ig (Fig. 
1a). Interestingly, however, TCR ~-chain contains a 
unique inserted sequence element between the second 
cysteine residue of the constant domain and the last 
cysteine residue which forms an inter-chain disulfide 
bridge with the a-chain. Whether this inserted se-
quence element is located within the constant domain 
or in the stem loop region between the constant 
domain and the transmembrane segment was not 
clear due to low sequence homology around this re-
gion. Therefore we made two additional constructs 
(~2.10-M and ~2.10-S) to see whether the inserted se-
quence element is important for proper folding of the 
~-chain TCR. Both ~2.10-M and ~2.10-S poly-
peptides were expressed in large quantities as in-
clusion bodies in E. coli, but unlike ~2.1O-L and ~2. 
10-M, ~2 . 10-S was not refolded at all, suggesting 
that ~2.10-S is lacking an essential component for 
proper folding. This suggests that the unique inserted 
sequence element found in TCR ~-chains could be lo-
cated within the constant domain and the sequence 
element must be important for maintaining the ter-
tiary structure of ~-chain TCR. X-ray crystal structure 
of a murine ~-chain TCR determined recently 
(Bentley et at., 1995) clearly shows that the inserted 
sequence element forms a long loop between the 
sixth and seventh ~-strands of the constant domain, 
and the loop is located at the interface between the 
variable domain and constant domain. 
This study showed that TCR ~-chain could be re-
folded in vitro without a-chain. Garboczi et al. (1996) 
has also observed that TCR a-chain and ~-chain 
could be refolded separately and assembled properly 
by mixing refolded a- and ~-chains together. These 
results suggest a possibility that the TCR a-chain and 
~-chain are capable of forming a homodimer and het-
erodimer depending on the circumstances although 
the propensity could be different. To address the ques-
tion about the oligomeric state of the ~-chain TCR, 
we determined the molecular weight by gel-filtration 
chromatography and performed chemical cross-link-
ing experiments with DSP. The apparent molecular 
mass of ~-chain TCR determined by FPLC gel-fil-
tration chromatography was about 60 kDa suggesting 
that it could exist as a dimer. However, inter-
molecular cross-linking of ~-chain TCR was not ob-
served by chemical crosslinking reactions with DSP. 
In addition, X-ray crystal structure of a murine ~­
chain TCR shows that it exists as a monomer in cry-
stals (Bentley et aI., 1995). Further experiments are 
necessary to clarify the oligomeric state of ~-chain 
TCR. 
The refolded ~-chain TCR seems to be folded cor-
rectly judging from the following observations. First, 
the refolded ~-chain TCR was very soluble and 
stable for at least one month, and it behaved like a 
normal soluble protein on gel-filtration chro-
matography and nondenaturingldenaturing PAGE. 
Second, the ~-chain TCR crystallized under the buf-
fer conditions of 15% PEG4K, 5 mM DTT, and 100 
mM HEPES (PH 7.5). Third, the ~-chain TCR binds 
specifically to TSST-1, a natural ligand (Fig. 3). 
Fourth, ELISA results indicate that the ~-chain TCR 
binds an anti-TCR monoclonal antibody that re-
cognizes the constant domain of TCR ~-chain (data 
not shown). 
The refolded ~-chain TCR (~2.10) was shown to 
bind to TSST-1, but not to SEB (Fig. 3). This result 
suggests that the soluble form of the ~-chain TCR is 
a proper ligand for TSST-1 and the binding in-
teraction is specific. The specificity of the binding in-
teraction of ~2.10 TCR and TSST -1 is further sup-
ported by the fact that the ~6.4 TCR prepared sim-
ilarly does not bind to TSST-1. 
The binding affinity of superantigen and a soluble 
form of a~ TCR or ~-chain TCR has been measured 
by surface plasmon resonance detection technique 
and sedimentation equilibrium technique (Malchiod et 
at. , 1995; Seth et at., 1994). The equilibrium dis-
sociation constant (Kd) of a~ TCR:SEB complex is 
0.82 IlM and those of a murine ~-chain TCR and 
SEC1, 2, and 3 are 2.51 IlM, 2.32 IlM, and 0.86 IlM, 
respectively. The binding constant of TSST-l:~-chain 
TCR complex formation has not been determined, 
but our data indicate that the binding affinity of 
TSST -1 and the ~-chain TCR is strong enough to be 
detected by native gel shift assay and to allow pu-
rification of the complex by gel-filtration chro-
matography. Furthermore, TSST-1:~-chain TCR com-
plex crystallized under the buffer conditions of 15% 
PEG4K, 5% isopropanol, and 100 mM HEPES (PH 
7.5). SDS PAGE analysis of the washed crystals re-
vealed that two proteins, TSST-1 and ~-chain TCR, 
are present in the crystals (data not shown). This 
result also suggests that the binding affinity of TSST-
1 and ~-chain TCR is strong enough to be analyzed 
by X-ray crystallography. 
TCR ~-chain is known to play an important role in 
the early development of T-cells in the thymus 
(Groettrup et at., 1992; Kishi et at., 1995; Mombaerts 
et aI., 1992; Shinkai et at. , 1993). The nature of the 
~-chain TCR expressed on premature T-cells awaits 
further characterization. However, the observation 
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that the TCR ~-chain can be refolded by itself sup-
ports the notion that it could exist stably on the sur-
face of certain T-cells and that it could have a func-
tional role in the development of T-cells. The a-
vailability of cDNA and soluble protein of TCR ~­
chain will also be useful in investigating the structure 
and functional role of the ~-chain TCR in the de-
velopment of T -cells. 
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